JP2002517999A - 抗血管形成タンパク質およびその使用方法 - Google Patents

Info

Publication number

JP2002517999A

JP2002517999A JP2000554765A JP2000554765A JP2002517999A JP 2002517999 A JP2002517999 A JP 2002517999A JP 2000554765 A JP2000554765 A JP 2000554765A JP 2000554765 A JP2000554765 A JP 2000554765A JP 2002517999 A JP2002517999 A JP 2002517999A

Authority

JP

Japan

Prior art keywords

protein

cells

angiogenic

fragment

tumstatin

Prior art date

1998-06-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000623 proteins and genes Proteins 0.000 title claims abstract description 406
• 102000004169 proteins and genes Human genes 0.000 title claims abstract description 348
• 230000001772 anti-angiogenic effect Effects 0.000 title claims abstract description 192
• 238000000034 method Methods 0.000 title claims abstract description 133
• 230000033115 angiogenesis Effects 0.000 claims abstract description 66
• 210000004027 cell Anatomy 0.000 claims description 292
• 108010012374 type IV collagen alpha3 chain Proteins 0.000 claims description 203
• 102400000731 Tumstatin Human genes 0.000 claims description 198
• FNQQBFNIYODEMB-UHFFFAOYSA-N Meticrane Chemical compound C1CCS(=O)(=O)C2=C1C=C(C)C(S(N)(=O)=O)=C2 FNQQBFNIYODEMB-UHFFFAOYSA-N 0.000 claims description 193
• 229960003738 meticrane Drugs 0.000 claims description 193
• 101800001248 Arresten Proteins 0.000 claims description 192
• 102400000729 Arresten Human genes 0.000 claims description 192
• 101800000626 Canstatin Proteins 0.000 claims description 166
• 102400000730 Canstatin Human genes 0.000 claims description 166
• 239000012634 fragment Substances 0.000 claims description 146
• 206010028980 Neoplasm Diseases 0.000 claims description 136
• 239000000203 mixture Substances 0.000 claims description 72
• 102000040430 polynucleotide Human genes 0.000 claims description 61
• 108091033319 polynucleotide Proteins 0.000 claims description 61
• 239000002157 polynucleotide Substances 0.000 claims description 61
• 108010079505 Endostatins Proteins 0.000 claims description 60
• 102400001047 Endostatin Human genes 0.000 claims description 59
• 108020001507 fusion proteins Proteins 0.000 claims description 57
• 102000037865 fusion proteins Human genes 0.000 claims description 57
• 102400001048 Non-collagenous domain 1 Human genes 0.000 claims description 52
• 101800000353 Non-collagenous domain 1 Proteins 0.000 claims description 52
• 230000014509 gene expression Effects 0.000 claims description 48
• 108010042086 Collagen Type IV Proteins 0.000 claims description 42
• 102000004266 Collagen Type IV Human genes 0.000 claims description 42
• 150000001413 amino acids Chemical class 0.000 claims description 42
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
• 210000001519 tissue Anatomy 0.000 claims description 40
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
• 238000001727 in vivo Methods 0.000 claims description 38
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 38
• 229920001184 polypeptide Polymers 0.000 claims description 35
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
• 201000010099 disease Diseases 0.000 claims description 30
• 230000002401 inhibitory effect Effects 0.000 claims description 29
• 230000005764 inhibitory process Effects 0.000 claims description 17
• 241000124008 Mammalia Species 0.000 claims description 16
• 239000002773 nucleotide Substances 0.000 claims description 16
• 125000003729 nucleotide group Chemical group 0.000 claims description 16
• 239000004480 active ingredient Substances 0.000 claims description 15
• 201000011510 cancer Diseases 0.000 claims description 15
• 238000010367 cloning Methods 0.000 claims description 15
• 238000000338 in vitro Methods 0.000 claims description 14
• 239000000178 monomer Substances 0.000 claims description 14
• 230000002792 vascular Effects 0.000 claims description 14
• 102400000068 Angiostatin Human genes 0.000 claims description 13
• 108010079709 Angiostatins Proteins 0.000 claims description 13
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 13
• 239000000523 sample Substances 0.000 claims description 13
• 238000004519 manufacturing process Methods 0.000 claims description 12
• 230000002491 angiogenic effect Effects 0.000 claims description 11
• 230000001580 bacterial effect Effects 0.000 claims description 11
• 102000008186 Collagen Human genes 0.000 claims description 10
• 108010035532 Collagen Proteins 0.000 claims description 10
• 229920001436 collagen Polymers 0.000 claims description 10
• 239000013603 viral vector Substances 0.000 claims description 9
• 210000004881 tumor cell Anatomy 0.000 claims description 8
• 230000001419 dependent effect Effects 0.000 claims description 7
• 230000029087 digestion Effects 0.000 claims description 7
• 102000016387 Pancreatic elastase Human genes 0.000 claims description 6
• 108010067372 Pancreatic elastase Proteins 0.000 claims description 6
• 241000589516 Pseudomonas Species 0.000 claims description 6
• 238000002512 chemotherapy Methods 0.000 claims description 6
• 238000000502 dialysis Methods 0.000 claims description 6
• 206010029113 Neovascularisation Diseases 0.000 claims description 5
• 210000003494 hepatocyte Anatomy 0.000 claims description 5
• 238000001959 radiotherapy Methods 0.000 claims description 5
• 241000238631 Hexapoda Species 0.000 claims description 4
• 102400001051 Restin Human genes 0.000 claims description 4
• 108010038764 cytoplasmic linker protein 170 Proteins 0.000 claims description 4
• 206010020718 hyperplasia Diseases 0.000 claims description 4
• 238000009169 immunotherapy Methods 0.000 claims description 4
• 230000002390 hyperplastic effect Effects 0.000 claims description 3
• 210000000663 muscle cell Anatomy 0.000 claims description 3
• 206010000050 Abdominal adhesions Diseases 0.000 claims description 2
• 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
• 208000003732 Cat-scratch disease Diseases 0.000 claims description 2
• 208000032544 Cicatrix Diseases 0.000 claims description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
• 241000590002 Helicobacter pylori Species 0.000 claims description 2
• 208000008589 Obesity Diseases 0.000 claims description 2
• 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
• 201000004681 Psoriasis Diseases 0.000 claims description 2
• 206010039710 Scleroderma Diseases 0.000 claims description 2
• 206010043189 Telangiectasia Diseases 0.000 claims description 2
• 208000025865 Ulcer Diseases 0.000 claims description 2
• 208000013058 Weber syndrome Diseases 0.000 claims description 2
• 206010052428 Wound Diseases 0.000 claims description 2
• 208000027418 Wounds and injury Diseases 0.000 claims description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
• 201000007293 brain stem infarction Diseases 0.000 claims description 2
• 238000005469 granulation Methods 0.000 claims description 2
• 230000003179 granulation Effects 0.000 claims description 2
• 229940037467 helicobacter pylori Drugs 0.000 claims description 2
• 230000035772 mutation Effects 0.000 claims description 2
• 230000002107 myocardial effect Effects 0.000 claims description 2
• 235000020824 obesity Nutrition 0.000 claims description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
• 231100000241 scar Toxicity 0.000 claims description 2
• 230000037387 scars Effects 0.000 claims description 2
• 230000036262 stenosis Effects 0.000 claims description 2
• 208000037804 stenosis Diseases 0.000 claims description 2
• 208000009056 telangiectasis Diseases 0.000 claims description 2
• 231100000397 ulcer Toxicity 0.000 claims description 2
• 210000004962 mammalian cell Anatomy 0.000 claims 3
• 210000005253 yeast cell Anatomy 0.000 claims 2
• 230000002137 anti-vascular effect Effects 0.000 claims 1
• 210000000601 blood cell Anatomy 0.000 claims 1
• 210000002950 fibroblast Anatomy 0.000 claims 1
• 201000002222 hemangioblastoma Diseases 0.000 claims 1
• 208000000509 infertility Diseases 0.000 claims 1
• 230000036512 infertility Effects 0.000 claims 1
• 231100000535 infertility Toxicity 0.000 claims 1
• 230000010474 transient expression Effects 0.000 claims 1
• 210000005167 vascular cell Anatomy 0.000 claims 1
• 235000018102 proteins Nutrition 0.000 description 294
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 70
• 238000011282 treatment Methods 0.000 description 69
• 239000013598 vector Substances 0.000 description 63
• 241000699670 Mus sp. Species 0.000 description 60
• 230000015572 biosynthetic process Effects 0.000 description 55
• 230000000694 effects Effects 0.000 description 53
• 108020004414 DNA Proteins 0.000 description 47
• 238000012937 correction Methods 0.000 description 45
• 235000001014 amino acid Nutrition 0.000 description 44
• 229940024606 amino acid Drugs 0.000 description 42
• 210000002889 endothelial cell Anatomy 0.000 description 41
• 230000003511 endothelial effect Effects 0.000 description 40
• 239000012894 fetal calf serum Substances 0.000 description 37
• 102000005962 receptors Human genes 0.000 description 35
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 34
• 229940098773 bovine serum albumin Drugs 0.000 description 33
• 150000007523 nucleic acids Chemical group 0.000 description 33
• 210000002469 basement membrane Anatomy 0.000 description 32
• 108020003175 receptors Proteins 0.000 description 32
• 238000003556 assay Methods 0.000 description 30
• 241000588724 Escherichia coli Species 0.000 description 28
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 27
• 102000039446 nucleic acids Human genes 0.000 description 26
• 108020004707 nucleic acids Proteins 0.000 description 26
• 230000004614 tumor growth Effects 0.000 description 26
• 108010082117 matrigel Proteins 0.000 description 25
• 210000004204 blood vessel Anatomy 0.000 description 23
• 230000012010 growth Effects 0.000 description 23
• 239000000126 substance Substances 0.000 description 23
• 230000004927 fusion Effects 0.000 description 22
• 230000008859 change Effects 0.000 description 21
• 239000013612 plasmid Substances 0.000 description 20
• 229940104230 thymidine Drugs 0.000 description 20
• 238000012546 transfer Methods 0.000 description 20
• 241001465754 Metazoa Species 0.000 description 19
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 19
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 19
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 19
• 238000009739 binding Methods 0.000 description 19
• 238000009472 formulation Methods 0.000 description 19
• 239000002609 medium Substances 0.000 description 19
• 230000004663 cell proliferation Effects 0.000 description 18
• 238000010348 incorporation Methods 0.000 description 18
• 239000000047 product Substances 0.000 description 18
• 230000002441 reversible effect Effects 0.000 description 18
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 17
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 17
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 16
• 150000001875 compounds Chemical class 0.000 description 16
• 230000006870 function Effects 0.000 description 16
• 239000007787 solid Substances 0.000 description 16
• 239000006228 supernatant Substances 0.000 description 16
• 235000014304 histidine Nutrition 0.000 description 15
• 230000008569 process Effects 0.000 description 15
• 208000006265 Renal cell carcinoma Diseases 0.000 description 14
• 238000002474 experimental method Methods 0.000 description 14
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 14
• 230000001225 therapeutic effect Effects 0.000 description 14
• 241000699666 Mus <mouse, genus> Species 0.000 description 13
• 238000004458 analytical method Methods 0.000 description 13
• 238000001415 gene therapy Methods 0.000 description 13
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 13
• 239000007924 injection Substances 0.000 description 13
• 238000002347 injection Methods 0.000 description 13
• 210000003734 kidney Anatomy 0.000 description 13
• 210000000056 organ Anatomy 0.000 description 13
• 150000003839 salts Chemical class 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 12
• -1 amine hydrochloride Chemical class 0.000 description 12
• 239000002299 complementary DNA Substances 0.000 description 12
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
• 208000008839 Kidney Neoplasms Diseases 0.000 description 11
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 11
• 238000005516 engineering process Methods 0.000 description 11
• 239000002502 liposome Substances 0.000 description 11
• 238000013508 migration Methods 0.000 description 11
• 230000035755 proliferation Effects 0.000 description 11
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 10
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
• 241000700605 Viruses Species 0.000 description 10
• 238000011717 athymic nude mouse Methods 0.000 description 10
• 239000003795 chemical substances by application Substances 0.000 description 10
• 229940127089 cytotoxic agent Drugs 0.000 description 10
• 238000006467 substitution reaction Methods 0.000 description 10
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 9
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 9
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
• 239000004472 Lysine Substances 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 239000004037 angiogenesis inhibitor Substances 0.000 description 9
• 230000000975 bioactive effect Effects 0.000 description 9
• 230000000875 corresponding effect Effects 0.000 description 9
• 229940088598 enzyme Drugs 0.000 description 9
• 125000005647 linker group Chemical group 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 239000002245 particle Substances 0.000 description 9
• 239000008194 pharmaceutical composition Substances 0.000 description 9
• 230000002062 proliferating effect Effects 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 230000001105 regulatory effect Effects 0.000 description 9
• 210000002966 serum Anatomy 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• 230000014616 translation Effects 0.000 description 9
• 238000005406 washing Methods 0.000 description 9
• 101710151806 72 kDa type IV collagenase Proteins 0.000 description 8
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 8
• 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 8
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 8
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
• 206010027476 Metastases Diseases 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 125000000539 amino acid group Chemical group 0.000 description 8
• 239000004202 carbamide Substances 0.000 description 8
• 238000002955 isolation Methods 0.000 description 8
• 230000007774 longterm Effects 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 230000005012 migration Effects 0.000 description 8
• 101150040383 pel2 gene Proteins 0.000 description 8
• 101150050446 pelB gene Proteins 0.000 description 8
• 238000013519 translation Methods 0.000 description 8
• 230000029663 wound healing Effects 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 7
• 241000700159 Rattus Species 0.000 description 7
• 239000005557 antagonist Substances 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 239000000969 carrier Substances 0.000 description 7
• 230000012292 cell migration Effects 0.000 description 7
• 238000010586 diagram Methods 0.000 description 7
• 238000010790 dilution Methods 0.000 description 7
• 239000012895 dilution Substances 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 230000010595 endothelial cell migration Effects 0.000 description 7
• 210000003527 eukaryotic cell Anatomy 0.000 description 7
• 239000013604 expression vector Substances 0.000 description 7
• 238000003119 immunoblot Methods 0.000 description 7
• 238000003780 insertion Methods 0.000 description 7
• 230000037431 insertion Effects 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 230000009401 metastasis Effects 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 239000011734 sodium Substances 0.000 description 7
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
• 208000024869 Goodpasture syndrome Diseases 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 206010038389 Renal cancer Diseases 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 238000000692 Student's t-test Methods 0.000 description 6
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 6
• 210000002403 aortic endothelial cell Anatomy 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 239000013599 cloning vector Substances 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 239000000539 dimer Substances 0.000 description 6
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 201000010982 kidney cancer Diseases 0.000 description 6
• 210000003292 kidney cell Anatomy 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 150000002632 lipids Chemical class 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 6
• 229960000907 methylthioninium chloride Drugs 0.000 description 6
• 239000008188 pellet Substances 0.000 description 6
• 210000002826 placenta Anatomy 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 239000000651 prodrug Substances 0.000 description 6
• 229940002612 prodrug Drugs 0.000 description 6
• 230000001177 retroviral effect Effects 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 108091026890 Coding region Proteins 0.000 description 5
• 241000196324 Embryophyta Species 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 108060003951 Immunoglobulin Proteins 0.000 description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
• 108010052285 Membrane Proteins Proteins 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 239000000556 agonist Substances 0.000 description 5
• 239000003242 anti bacterial agent Substances 0.000 description 5
• 239000002246 antineoplastic agent Substances 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 229910002091 carbon monoxide Inorganic materials 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 239000002254 cytotoxic agent Substances 0.000 description 5
• 231100000599 cytotoxic agent Toxicity 0.000 description 5
• 238000009826 distribution Methods 0.000 description 5
• 231100000673 dose–response relationship Toxicity 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 239000003814 drug Substances 0.000 description 5
• 210000003038 endothelium Anatomy 0.000 description 5
• 230000001605 fetal effect Effects 0.000 description 5
• 238000009396 hybridization Methods 0.000 description 5
• 102000018358 immunoglobulin Human genes 0.000 description 5
• 230000006698 induction Effects 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 239000007928 intraperitoneal injection Substances 0.000 description 5
• 230000004807 localization Effects 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 230000001717 pathogenic effect Effects 0.000 description 5
• 229920002704 polyhistidine Polymers 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 5
• 239000002464 receptor antagonist Substances 0.000 description 5
• 229940044551 receptor antagonist Drugs 0.000 description 5
• 239000012134 supernatant fraction Substances 0.000 description 5
• 238000001890 transfection Methods 0.000 description 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
• 241000701161 unidentified adenovirus Species 0.000 description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
• 229920000936 Agarose Polymers 0.000 description 4
• 239000004475 Arginine Substances 0.000 description 4
• 241000283690 Bos taurus Species 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 108010001857 Cell Surface Receptors Proteins 0.000 description 4
• 108010067306 Fibronectins Proteins 0.000 description 4
• 102000016359 Fibronectins Human genes 0.000 description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 4
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 4
• 102000018697 Membrane Proteins Human genes 0.000 description 4
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 238000002835 absorbance Methods 0.000 description 4
• 238000001042 affinity chromatography Methods 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 229940088710 antibiotic agent Drugs 0.000 description 4
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
• 230000003115 biocidal effect Effects 0.000 description 4
• 230000015556 catabolic process Effects 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 230000035605 chemotaxis Effects 0.000 description 4
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 4
• 238000004520 electroporation Methods 0.000 description 4
• 239000000834 fixative Substances 0.000 description 4
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 239000003102 growth factor Substances 0.000 description 4
• 238000011065 in-situ storage Methods 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 150000007524 organic acids Chemical class 0.000 description 4
• 239000012188 paraffin wax Substances 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 229920000747 poly(lactic acid) Polymers 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 229940044601 receptor agonist Drugs 0.000 description 4
• 239000000018 receptor agonist Substances 0.000 description 4
• 238000010188 recombinant method Methods 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 210000001082 somatic cell Anatomy 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 238000013268 sustained release Methods 0.000 description 4
• 239000012730 sustained-release form Substances 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• 210000003606 umbilical vein Anatomy 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 102000003916 Arrestin Human genes 0.000 description 3
• 108090000328 Arrestin Proteins 0.000 description 3
• 208000023275 Autoimmune disease Diseases 0.000 description 3
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101500026840 Homo sapiens Arresten Proteins 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
• 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 229920000954 Polyglycolide Polymers 0.000 description 3
• 108010039918 Polylysine Proteins 0.000 description 3
• 206010060862 Prostate cancer Diseases 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 3
• 239000002870 angiogenesis inducing agent Substances 0.000 description 3
• 238000011122 anti-angiogenic therapy Methods 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 229920002988 biodegradable polymer Polymers 0.000 description 3
• 239000004621 biodegradable polymer Substances 0.000 description 3
• 210000001124 body fluid Anatomy 0.000 description 3
• 239000010839 body fluid Substances 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 239000001110 calcium chloride Substances 0.000 description 3
• 229910001628 calcium chloride Inorganic materials 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 239000002975 chemoattractant Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000030944 contact inhibition Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 230000000593 degrading effect Effects 0.000 description 3
• 230000008021 deposition Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 238000002405 diagnostic procedure Methods 0.000 description 3
• 239000010432 diamond Substances 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 210000005003 heart tissue Anatomy 0.000 description 3
• 229920000669 heparin Polymers 0.000 description 3
• 229960002897 heparin Drugs 0.000 description 3
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
• 102000006495 integrins Human genes 0.000 description 3
• 108010044426 integrins Proteins 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 150000007522 mineralic acids Chemical class 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 230000010046 negative regulation of endothelial cell proliferation Effects 0.000 description 3
• 238000004806 packaging method and process Methods 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 229920000656 polylysine Polymers 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 238000004393 prognosis Methods 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 238000010361 transduction Methods 0.000 description 3
• 230000026683 transduction Effects 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 239000013638 trimer Substances 0.000 description 3
• 210000005239 tubule Anatomy 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• 210000005166 vasculature Anatomy 0.000 description 3
• 230000000007 visual effect Effects 0.000 description 3
• AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 102000008076 Angiogenic Proteins Human genes 0.000 description 2
• 108010074415 Angiogenic Proteins Proteins 0.000 description 2
• 108010032595 Antibody Binding Sites Proteins 0.000 description 2
• IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
• 101000946068 Caenorhabditis elegans Ceramide glucosyltransferase 3 Proteins 0.000 description 2
• 101710132601 Capsid protein Proteins 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 206010020880 Hypertrophy Diseases 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 206010061216 Infarction Diseases 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 206010037394 Pulmonary haemorrhage Diseases 0.000 description 2
• 239000008156 Ringer's lactate solution Substances 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 108010006886 Vitrogen Proteins 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• 230000001028 anti-proliverative effect Effects 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
• 238000003491 array Methods 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 238000000376 autoradiography Methods 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 238000010170 biological method Methods 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 210000001043 capillary endothelial cell Anatomy 0.000 description 2
• 230000021164 cell adhesion Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 239000013256 coordination polymer Substances 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 239000008355 dextrose injection Substances 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 238000007865 diluting Methods 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 230000002500 effect on skin Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 210000003989 endothelium vascular Anatomy 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 238000001400 expression cloning Methods 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 238000001641 gel filtration chromatography Methods 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 238000010353 genetic engineering Methods 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 230000001434 glomerular Effects 0.000 description 2
• 210000000585 glomerular basement membrane Anatomy 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 235000004554 glutamine Nutrition 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 150000002411 histidines Chemical class 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 238000010166 immunofluorescence Methods 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000010874 in vitro model Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000007972 injectable composition Substances 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 238000002642 intravenous therapy Methods 0.000 description 2
• 230000007794 irritation Effects 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 239000004310 lactic acid Substances 0.000 description 2
• 235000014655 lactic acid Nutrition 0.000 description 2
• 239000006193 liquid solution Substances 0.000 description 2
• 239000006194 liquid suspension Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 239000003068 molecular probe Substances 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 235000011007 phosphoric acid Nutrition 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• 239000004417 polycarbonate Substances 0.000 description 2
• 229920000515 polycarbonate Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 239000011148 porous material Substances 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 230000033458 reproduction Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 102220240796 rs553605556 Human genes 0.000 description 2
• 239000008354 sodium chloride injection Substances 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 230000017105 transposition Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 238000012447 xenograft mouse model Methods 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical class C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Chemical group OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical group ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
• VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
• VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
• MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
• DETXZQGDWUJKMO-UHFFFAOYSA-N 2-hydroxymethanesulfonic acid Chemical compound OCS(O)(=O)=O DETXZQGDWUJKMO-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Chemical group CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
• AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 1
• SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
• 229940117976 5-hydroxylysine Drugs 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 208000031295 Animal disease Diseases 0.000 description 1
• 108010002913 Asialoglycoproteins Proteins 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 108090000565 Capsid Proteins Proteins 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 102100023321 Ceruloplasmin Human genes 0.000 description 1
• 229920001287 Chondroitin sulfate Polymers 0.000 description 1
• 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 208000028399 Critical Illness Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 108010072210 Cyclophilin C Proteins 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 241000450599 DNA viruses Species 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 238000009007 Diagnostic Kit Methods 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 108010040476 FITC-annexin A5 Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000009292 Hemophilia A Diseases 0.000 description 1
• 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
• 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
• 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
• 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
• 101500024044 Homo sapiens Tumstatin Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 102100038609 Lactoperoxidase Human genes 0.000 description 1
• 108010023244 Lactoperoxidase Chemical group 0.000 description 1
• 108010085895 Laminin Proteins 0.000 description 1
• 102000007547 Laminin Human genes 0.000 description 1
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
• 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
• 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 102100034256 Mucin-1 Human genes 0.000 description 1
• 101500026380 Mus musculus Endostatin Proteins 0.000 description 1
• 101100153331 Mus musculus Timp1 gene Proteins 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical group CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 102100037369 Nidogen-1 Human genes 0.000 description 1
• 102000011931 Nucleoproteins Human genes 0.000 description 1
• 108010061100 Nucleoproteins Proteins 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 description 1
• 101710204736 Platelet endothelial cell adhesion molecule Proteins 0.000 description 1
• 102000004211 Platelet factor 4 Human genes 0.000 description 1
• 108090000778 Platelet factor 4 Proteins 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
• 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 108010076039 Polyproteins Proteins 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 241000710960 Sindbis virus Species 0.000 description 1
• 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 108090000054 Syndecan-2 Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
• 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• 108010087302 Viral Structural Proteins Proteins 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
• GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• 238000003277 amino acid sequence analysis Methods 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 210000002159 anterior chamber Anatomy 0.000 description 1
• 230000003527 anti-angiogenesis Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• ZRUWFKRETRELPY-UHFFFAOYSA-N azane;nickel(2+) Chemical compound N.[Ni+2] ZRUWFKRETRELPY-UHFFFAOYSA-N 0.000 description 1
• XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
• 229950001858 batimastat Drugs 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 238000005422 blasting Methods 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 210000004900 c-terminal fragment Anatomy 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229940087373 calcium oxide Drugs 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
• 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 229940059329 chondroitin sulfate Drugs 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
• 229960005188 collagen Drugs 0.000 description 1
• 230000007691 collagen metabolic process Effects 0.000 description 1
• 229960002424 collagenase Drugs 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 210000004246 corpus luteum Anatomy 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 210000000448 cultured tumor cell Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 231100000517 death Toxicity 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Chemical group NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 238000000326 densiometry Methods 0.000 description 1
• 210000002555 descemet membrane Anatomy 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 150000008050 dialkyl sulfates Chemical class 0.000 description 1
• LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical group CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 230000032692 embryo implantation Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
• 108700004025 env Genes Proteins 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000007071 enzymatic hydrolysis Effects 0.000 description 1
• 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
• 238000009585 enzyme analysis Methods 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 229960004887 ferric hydroxide Drugs 0.000 description 1
• 230000008175 fetal development Effects 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000000799 fusogenic effect Effects 0.000 description 1
• 108700004026 gag Genes Proteins 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 230000035784 germination Effects 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 230000036252 glycation Effects 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 244000144993 groups of animals Species 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
• 235000011167 hydrochloric acid Nutrition 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000037189 immune system physiology Effects 0.000 description 1
• 238000010820 immunofluorescence microscopy Methods 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 210000001865 kupffer cell Anatomy 0.000 description 1
• 229940057428 lactoperoxidase Drugs 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 208000037841 lung tumor Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 238000000691 measurement method Methods 0.000 description 1
• 238000010297 mechanical methods and process Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 238000001000 micrograph Methods 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 108010008217 nidogen Proteins 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 229940099990 ogen Drugs 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000004786 perivascular cell Anatomy 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000008196 pharmacological composition Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 108700004029 pol Genes Proteins 0.000 description 1
• 239000002745 poly(ortho ester) Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 210000000064 prostate epithelial cell Anatomy 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 108010015249 protease XXIV Proteins 0.000 description 1
• 229940076376 protein agonist Drugs 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 210000001147 pulmonary artery Anatomy 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 229910052702 rhenium Inorganic materials 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000012192 staining solution Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000005728 strengthening Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 235000011044 succinic acid Nutrition 0.000 description 1
• 150000003444 succinic acids Chemical class 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 206010044325 trachoma Diseases 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 239000010937 tungsten Substances 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 230000009107 upstream regulation Effects 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1